Wall Street analysts forecast that Becton Dickinson (BDX Quick QuoteBDX - Free Report) will report quarterly earnings of $4.06 per share in its upcoming release, pointing to a year-over-year increase of 2.5%. It is anticipated that revenues will amount to $5.12 billion, exhibiting a decrease of 13% compared to the year-ago quarter.

Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.

That said, let's delve into the average estimates of some Becton Dickinson metrics that Wall Street analysts commonly model and monitor.

Analysts predict that the 'Revenues- Medical Essentials' will reach $1.71 billion. The estimate points to a change of -45.8% from the year-ago quarter.

Analysts expect 'Revenues- Interventional' to come in at $1.42 billion. The estimate indicates a year-over-year change of +3.7%.

The collective assessment of analysts points to an estimated 'Revenues- Connected Care- Medication Management Solutions' of $964.46 million. The estimate points to a change of -1% from the year-ago quarter.

Analysts' assessment points toward 'Revenues- Interventional- Urology and Critical Care' reaching $459.84 million. The estimate indicates a year-over-year change of +5.2%.

The combined assessment of analysts suggests that 'Revenues- Connected Care- Medication Management Solutions- International' will likely reach $203.19 million. The estimate points to a change of +4.7% from the year-ago quarter.

The consensus among analysts is that 'Revenues- Connected Care- Medication Management Solutions- United States' will reach $765.50 million. The estimate indicates a change of -1.9% from the prior-year quarter.

The consensus estimate for 'Revenues- Interventional- Peripheral Intervention- United States' stands at $290.82 million. The estimate points to a change of +5.8% from the year-ago quarter.

Analysts forecast 'Revenues- Interventional- Urology and Critical Care- United States' to reach $364.87 million. The estimate points to a change of +7% from the year-ago quarter.

According to the collective judgment of analysts, 'Revenues- Interventional- United States' should come in at $958.73 million. The estimate points to a change of +5.9% from the year-ago quarter.

Based on the collective assessment of analysts, 'Revenues- Interventional- Surgery- International' should arrive at $113.62 million. The estimate indicates a change of +3.3% from the prior-year quarter.

The average prediction of analysts places 'Revenues- Interventional- Peripheral Intervention- International' at $258.27 million. The estimate points to a change of +0.9% from the year-ago quarter.

It is projected by analysts that the 'Revenues- Interventional- Urology and Critical Care- International' will reach $95.39 million. The estimate indicates a year-over-year change of -1.7%.

Shares of Becton Dickinson have experienced a change of +9.9% in the past month compared to the -2.3% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), BDX is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .